Hearing so much focus on executive dysfunction in recent years has been enlightening. I haven't always known the term, but executive dysfunction has been my thing since my inception. In the first ...
An embattled Oakland County judge is now accused of mental disability in the ongoing professional misconduct case against her ...
First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates.Restores global TDP-43 splicing ...
With the voice of its 30,000 professionals, the PGA of America is likely the grown-up in golf’s otherwise chaotic room. But ...
A $14.5M federal investment is seeding 10 new accrediting agencies. The question: genuine innovation or duplication of what ...
The Supreme Court of India's November 2025 judgment in Madras Bar Association v. Union of India (2025) may, at first glance, ...
As maddening as nonrestorative sleep night after night can be, the consequences go much deeper. Left unaddressed, sleep apnea ...
Belfast News Letter on MSN
All unionist parties united in criticism against O'Dowd budget proposals
The DUP has rejected John O’Dowd’s budget proposals – saying they are “deeply flawed” – telling the Sinn Fein minister to ...
NPA remains under executive control, hindering anti-corruption efforts.Mothibi appointed to guide NPA amid transition to new ...
Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead ...
Company to highlight outlook for pipeline and platform momentum in 2026SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a ...
Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback